Oncolytics Biotech Inc., a clinical-stage biopharmaceutical company, engages in the research, development, and commercialization of oncology treatments. The company develops pelareorep, an intravenously delivered immunotherapeutic agent for the treatment of gastrointestinal (?GI?) tumors, metastatic colorectal cancer, anal cancer, and metastatic pancreatic cancer. It has an agreement with Roche Holding AG to supply its immune checkpoint inhibitors, atezolizumab, for use in its ongoing sponsored studies. Oncolytics Biotech Inc. was incorporated in 1998 and is headquartered in San Diego, California.

• Download SqueezeTrigger (TM) Report
• Download FrictionFactor Report
• Download Daily Short Volume Report
• Download Real-Time Short Volume Tool
• Download Failures to Deliver

• [05/29/2026 12:42 PDT] Oncolytics Biotech Inc (NASDAQ:ONCY), Up By 100% ($0.83) From $0.827 After BUYINS.NET Report Predicted Stock Would Go Up Due To Bullish Conditions
• [05/29/2026 12:04 PDT] Oncolytics Biotech Inc (NASDAQ:ONCY), Up By 100% ($0.82) From $0.82 After BUYINS.NET Report Predicted Stock Would Go Up Due To Bullish Conditions
• [05/29/2026 12:04 PDT] Oncolytics Biotech Inc (NASDAQ:ONCY), Up By 100% ($0.81) From $0.807 After BUYINS.NET Report Predicted Stock Would Go Up Due To Bullish Conditions
• [05/28/2026 07:23 PDT] ONCY Expected to Trade Up After Bullish Patterns Develop
• [05/27/2026 07:43 PDT] ONCY Expected to Trade Up After Bullish Patterns Develop
• [05/22/2026 07:15 PDT] ONCY Expected to Trade Up After Bullish Patterns Develop
• [05/21/2026 06:57 PDT] ONCY Expected to Trade Up After Bullish Patterns Develop
• [04/22/2026 09:51 PDT] Oncolytics Biotech Inc (NASDAQ:ONCY), Up By 100% ($0.96) From $0.96 After BUYINS.NET Report Predicted Stock Would Go Up Due To Bullish Conditions
• [04/06/2026 07:09 PDT] ONCY Expected to Trade Up After Bullish Patterns Develop